Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure

Perin, Emerson C.; Willerson, James T.; Pepine, Carl J.; Henry, Timothy D.; Ellis, Stephen G.; Zhao, David; Silva, Guilherme V.; Lai, Dejian; Thomas, James D.; Kronenberg, Marvin W.; Martin, A. Daniel; Anderson, R. David; Traverse, Jay H.; Penn, Marc S.; Anwaruddin, Saif; Hatzopoulos, Antonis K.; Gee, Adrian P.; Taylor, Doris A.; Cogle, Christopher R.; Smith, Deirdre; Westbrook, Lynette; Chen, James; Handberg, Eileen M.; Olson, Rachel E.; Geither, Carrie; Bowman, Sherry; Francescon, Judy; Baraniuk, Sarah; Piller, Linda B.; Simpson, Lara M.; Loghin, Catalin; Aguilar, David; Richman, Sara; Zierold, Claudia; Bettencourt, Judy; Sayre, Shelly L.; Vojvodic, Rachel W.; Skarlatos, Sonia I.; Gordon, David; Ebert, Ray F.; Kwak, Minjung; Moyé, Lemuel A.; Simari, Robert D.

doi:10.1001/jama.2012.418

Cited by 433 publications

(306 citation statements)

References 41 publications

Supporting

Mentioning

288

Contrasting

Unclassified

Order By: Relevance

“…59,62 Intracoronary delivery has been used in AMI, 43 68,75 While others demonstrated no effect on EF, there were still benefits. 66,67,78,80,85,86 Using allogeneic multipotent cells via adventitial delivery, Penn et al 27 demonstrated a significant EF increase compared to results witnessed in other trials. There were no adverse effects or signs of infarction.…”

Section: Cell Delivery Comparisonsmentioning

confidence: 98%

“…83 STAR-Heart, the largest HF study, demonstrated improved ventricular function with significantly decreased mortality at 5 years. 79 Some trials did not show significant results, 76,85 while others demonstrated benefits, but no effect on EF. 66,67,74,77,80,84,86 A highly anticipated trial, FOCUS-CCTRN, assessed BMC via transendocardial injection in chronic HF.…”

Section: Clinical Outcomes Acute Myocardial Infarctionmentioning

confidence: 99%

See 1 more Smart Citation

Stem Cell Therapy for Heart Disease

2013

Self Cite

View full text Add to dashboard Cite

Coronary artery disease is the leading cause of death in Americans. After myocardial infarction, significant ventricular damage persists despite timely reperfusion and pharmacological management. Treatment is limited, as current modalities do not cure this damage. In the past decade, stem cell therapy has emerged as a promising therapeutic solution to restore myocardial function. Clinical trials have demonstrated safety and beneficial effects in patients suffering from acute myocardial infarction, heart failure, and dilated cardiomyopathy. These benefits include improved ventricular function, increased ejection fraction, and decreased infarct size. Mechanisms of therapy are still not clearly understood. However, it is believed that paracrine factors, including stromal cell-derived factor-1, contribute significantly to stem cell benefits. The purpose of this article is to provide medical professionals with an overview on stem cell therapy for the heart and to discuss potential future directions.

show abstract

Section: Cell Delivery Comparisonsmentioning

confidence: 98%

Section: Clinical Outcomes Acute Myocardial Infarctionmentioning

confidence: 99%

Stem Cell Therapy for Heart Disease

2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…human and animal models, to varying degrees of success [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] . In animal models, these cellbased therapies have demonstrated effectiveness in reducing infarct size and ventricular dilatation, and improving myocardial function [24][25][26] .…”

Section: Figurementioning

confidence: 99%

Cardiac Repair Using Stem Cells Conditioned Media Based Therapy in a Rodent Model of Myocardial Infarction and Heart Failure

Al-Refai¹,

Ridwan²,

Tarola³

et al. 2017

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…However, few patients are eligible or able to receive these treatments, although there are last-resort options, including insertion of a ventricular assist device and a heart transplant. Under these conditions, recent clinical studies [2][3][4] and animal experiments [5,6] have demonstrated the positive effects of stem cell transplantation on ischemic heart disease. Several methods have been proposed for transplanting stem cells into the heart, including transvenous infusion, interstitial retrograde coronary venous delivery, intracoronary arterial infusion, surgical transepicardial infusion using a cell sheet and transendocardial injection using a catheter [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…Although there are currently a few devices available for the intramyocardial delivery of cells [14][15][16][17][18], there are several aspects that require improvement. A few endomyocardial cell infusion devices have already been used in animal experiments and clinical trials [2,5,8,[16][17][18]. For example, the Myostar ™ catheter [2] requires an 8-Fr guiding catheter and does not have a mechanism for precise adjustment of the length and angle of the needle tip.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Device for Cell Delivery to the Myocardium: Validation in Swine Hearts

Yokawa¹,

Nakanishi²,

Mori³

et al. 2017

J Tissue Sci Eng

View full text Add to dashboard Cite

Background: Endocardial infusion is a minimally invasive procedure for cell delivery with good selectivity to the target region. However, certain limitations to current devices could affect the precision of the procedure and the therapeutic outcome. Therefore, we developed an enhanced device for transendocardial cell infusion. Methods and Results:Our device is based on an electrode-guided transendocardial bidirectional 75 cm long catheter and 0.5 mm diameter inner needle. The key advantages of our device are the slender catheter diameter (7 Fr), consistent needle tip length, regulation of the catheter angle and independence between the needle and catheter. Mesenchymal stem cells (MSCs) were obtained from the inguinal adipose tissue of six healthy swine and propagated through 2-3 passages. Using the catheter, pre-labeled MSCs were infused autogenously into the swine hearts. The MSCs-infused myocardial regions were harvested on the infusion day (day 0) or 2 days later, and histological analysis was performed. The MSCs were successfully infused into all six swine myocardia and distributed along the hole made by the needle. The spread area of MSCs was larger at 2 days after infusion than at day 0 (1.38 ± 0.26 vs. 0.51 ± 0.17 mm 2 /infusion, p=0.013). No complications occurred during the procedure, such as cardiac tamponade or arrhythmia.Conclusion: These results demonstrate that our enhanced device could be useful for delivering cells into the myocardium.

show abstract

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure

Cited by 433 publications

References 41 publications

Stem Cell Therapy for Heart Disease

Stem Cell Therapy for Heart Disease

Cardiac Repair Using Stem Cells Conditioned Media Based Therapy in a Rodent Model of Myocardial Infarction and Heart Failure

Enhanced Device for Cell Delivery to the Myocardium: Validation in Swine Hearts

Contact Info

Product

Resources

About